BioCardia Inc./$BCDA
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Ticker
$BCDA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
19
ISIN
US09060U6064
Website
BioCardia Inc. Metrics
BasicAdvanced
$11M
-
-$2.41
0.84
-
Price and volume
Market cap
$11M
Beta
0.84
52-week high
$3.20
52-week low
$1.73
Average daily volume
150K
Financial strength
Current ratio
0.363
Quick ratio
0.293
Long term debt to equity
-29.737
Total debt to equity
-55.921
Profitability
EBITDA (TTM)
-8.392
Gross margin (TTM)
-155,766.67%
Net profit margin (TTM)
-279,700.00%
Operating margin (TTM)
-281,733.33%
Management effectiveness
Return on assets (TTM)
-218.06%
Return on equity (TTM)
442.21%
Valuation
Price to revenue (TTM)
2,462.253
Price to book
-6.53
Price to tangible book (TTM)
-6.53
Price to free cash flow (TTM)
-0.91
Free cash flow yield (TTM)
-109.94%
Free cash flow per share (TTM)
-233.07%
Growth
Revenue change (TTM)
-99.36%
Earnings per share change (TTM)
-65.18%
3-year revenue growth (CAGR)
-85.72%
10-year revenue growth (CAGR)
-43.48%
3-year earnings per share growth (CAGR)
-40.48%
BioCardia Inc. News
AllArticlesVideos
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
GlobeNewsWire·1 month ago
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results
GlobeNewsWire·2 months ago
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioCardia Inc. stock?
BioCardia Inc. (BCDA) has a market cap of $11M as of July 05, 2025.
What is the P/E ratio for BioCardia Inc. stock?
The price to earnings (P/E) ratio for BioCardia Inc. (BCDA) stock is 0 as of July 05, 2025.
Does BioCardia Inc. stock pay dividends?
No, BioCardia Inc. (BCDA) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next BioCardia Inc. dividend payment date?
BioCardia Inc. (BCDA) stock does not pay dividends to its shareholders.
What is the beta indicator for BioCardia Inc.?
BioCardia Inc. (BCDA) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.